(R)-2,2,2-Trifluoro-1-phenylethylaminehydrochloride, 95.0%, 1g

Ethyl-(1-methyl-piperidin-4-yl)-amine, 95.0%, 5g

N-(4-Phenoxyphenyl)-1,3-benzothiazol-2-amine, 95%, 1g

2,4-dimethyl-1H-1,3-benzodiazole, 97%, 5g

4-chloro-6-(4-methyl-1-piperazinyl)-2-pyrimidinamine, 95.0%, 1g

Hydroxyde de sodium, min 98%, pa, ISO, en pastilles, 5 kg, emballage plastique.

2,5,8,11-Tetraoxatetradecan-14-oic acid, 95%, 5g

4-Bromocumene>97.0%(GC)5g

2-Cyanophenol>98.0%(GC)(T)25g

N-[(11bR)-2,6-Bis([1,1'-biphenyl]-4-yl)-4-oxidodinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl]-1,1,1-trifluoromethanesulfonamide, 98%, 100mg

4-BOC-AMINOMETHYL-BENZONITRILE, 97.0%, 25g

Ethyl 4-(3,4-dichlorophenyl)-4-oxobutyrate, 97.0%, 1g

(4-bromo-1-methyl-1H-pyrazol-5-yl)methanol, 95.0%, 250mg